Curis, Inc. (NASDAQ:CRIS) is expected to report third quarter earnings results, after market close, on Tuesday 10th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.13 per share from revenue of $ 2.57 million.
Looking ahead, the full year loss are expected at $ 0.66 per share on the revenues of $ 10.34 million.
Previous Quarter Performance
Curis, Inc. unwinded loss for the second quarter of $ 0.17 per share, from the revenue of $ 2.36 million. Street analysts expected Curis, Inc. to report loss of $ 0.19 per share on revenue of $ 2.63 million for the second quarter. The bottom line results beat street analysts by $ 0.02 or 10.53 percent, at the same time, top line results fell short of analysts by $ 0.27 million or 10.27 percent.
Stock Performance
Shares of Curis, Inc. traded low $ -0.04 or -3.57 percent on Monday, reaching $ 1.08 with volume of 547.80 thousand shares. Curis, Inc. has traded high as $ 1.16 and has cracked $ 1.07 on the downward trend
According to the previous trading day, closing price of $ 1.08, representing a 80.65 % increase from the 52 week low of $ 0.62 and a 68.8 % decrease over the 52 week high of $ 3.59.
The company has a market capital of $ 59.92 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Curis, Inc. will be hosting a conference call at 4:30 PM eastern time on 10th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.curis.com
Curis, Inc., a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. The company has collaboration agreement with F.
